Myo-inositol versus Metformin in Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis of Anthropometric, Endocrine, Metabolic, and Reproductive Outcomes
Abstract
Abstract
Background: : Polycystic ovary syndrome (PCOS) features metabolic and hyperandrogenic abnormalities. Myo-inositol and metformin are insulin-sensitizers with unclear comparative effectiveness.
Objectives: : : To compare the anthropometric, endocrine, metabolic, and reproductive effects of myo-inositol and metformin in women with PCOS. Search Strategy : PubMed, Google Scholar, and Cochrane Library were searched from inception through August 26, 2025, in accordance with (PRISMA 2020) guidelines. Selection Criteria: Thirty-Two randomized controlled trials and observational studies comparing myo-inositol with metformin in women with PCOS were included. Data Collection and Analysis: Anthropometric, endocrine, metabolic, reproductive outcomes, and adverse effects assessed at three and six months of treatment. Forest plots were generated using Review Manager 5.4. Sensitivity and subgroup analyses were conducted with R 4.5.2. Meta-regression was performed to explore sources of heterogeneity. Certainty of evidence was assessed using the GRADE approach. Main Results: Anthropometric outcomes included BMI at six months (SMD 0.20, 95% CI −0.09 to 0.93; p = 0.11) was comparable. Metabolic outcome fasting insulin at six months (SMD −0.16, 95% CI −0.70 to 0.38; p = 0.57) was similar. Endocrine outcomes favored myo-inositol for testosterone at three months (SMD −0.32; p = 0.04) and the LH/FSH ratio at six months (SMD −1.26; p = 0.04). Myo-inositol was associated with fewer adverse…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.